OTC · EMMA
Emmaus Life Sciences, Inc.
$0.04-$0.01 (-13.51%)
Emmaus Life Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.95% below the high.
Loading market information…
OTC · ORGS · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Orgenesis Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.87% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Orgenesis Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$2.60. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Orgenesis Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Orgenesis Inc. is a global biotechnology firm dedicated to the field of cell and gene therapies. The company has engineered an innovative Point of Care (POCare) platform. This system incorporates a portfolio of licensed POCare therapeutics, which are manufactured and prepared using automated, self-contained POCare technology within a cooperative network. Orgenesis primarily concentrates on autologous therapies, developing customized processes and systems for each treatment. These utilize a closed, automated processing methodology, validated for safe and compliant production directly at the patient's location, facilitating immediate therapeutic application. Established in 2008 as Business Outsourcing Service, Inc., the company adopted the name Orgenesis Inc. in August 2011 and is headquartered in Germantown, Maryland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:08 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2023 | Nov 13, 2023 | -$4.30-530.0% vs estimate | $110.00K-99.19% vs estimate |
|---|
| Q2 2023 | Aug 11, 2023 | -$1.50-350.0% vs estimate | $6.98M-34.81% vs estimate |
|---|
| Q1 2023 | May 10, 2023 | -$1.70-440.0% vs estimate | $7.04M-28.85% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.04-$0.01 (-13.51%)
Emmaus Life Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.95% below the high.
$0.06$0.00 (0.0%)
Unity Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.19% below the high.
$3.29$0.00 (0.0%)
Helix BioMedix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.38% below the high.
$0.02$0.00 (0.0%)
SQZ Biotechnologies Company’s quoted price sits in the lower half of its reported 52-week range, 65.71% below the high.
$0.00$0.00 (0.0%)
Neutra Corp.’s quoted price sits in the upper half of its reported 52-week range, 33.33% below the high.
$1.30+$0.27 (+26.21%)
Next Generation Management Corp.’s quoted price sits in the lower half of its reported 52-week range, 84.85% below the high.
€0.05€0.00 (0.0%)
Paion AG’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
$0.00$0.00 (0.0%)
Indocan Resources Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.0% below the high.
